Modifying empirical therapy for bloodstream infections when the pathogen is identified

Modify antimicrobial therapy for bloodstream infections, including sepsis or septic shock, as soon as additional information is available (eg source of infection, Gram stain, results of culture and susceptibility testing). If a pathogen has been identified and is consistent with the source of infection, de-escalate treatment according to the following pathogen-specific recommendations. However, in some cases (eg intra-abdominal sepsis associated with a perforated viscus) it is appropriate to continue empirical therapy targeted to the source of infection. Occasionally, an organism identified by culture (eg a coagulase-negative staphylococcus) is a contaminant. A clinical microbiologist or infectious diseases physician can assist with modifying therapy based on microbiological results and clinical progress.

Advice on directed therapy for bloodstream infections, including sepsis and septic shock, is included in these guidelines for the following pathogens:

Regimens for bacteraemia, including sepsis and septic shock, caused by enterococci, Clostridium species, Listeria monocytogenes and Neisseria meningitidis are not included in these guidelines. For drug choice, see:

In neonates, the choice of antimicrobials for directed therapy of bloodstream infections, including sepsis and septic shock is complex – seek expert advice. A regimen based on local protocols, or advice from a clinical microbiologist or infectious diseases physician improves outcomes. This is particularly important for neonates in the intensive care unit. Mortality is decreased when appropriate antibiotics are given early. Pathogen-specific regimens are included in these guidelines for: